Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 7/20 | 0.35 |
| ▸ | SYK | P43405 | 4/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | TEK | Q02763 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | BCL6 | P41182 | 1/20 | 0.34 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1298753 | 0.86 | LRRK2 (0.53) | LRRK2BRAFSYKAURKBMEN1 | |
| SCHEMBL1298402 | 0.86 | LRRK2 (0.55) | LRRK2SYKJAK2 | |
| SCHEMBL1298156 | 0.79 | WHR1 (0.39) | LRRK2BRAF | |
| SCHEMBL1298259 | 0.76 | LRRK2 (0.55) | LRRK2BRAFSYKAURKB | |
| SCHEMBL1298858 | 0.74 | LRRK2 (0.53) | LRRK2BRAFSYKJAK2 | |
| SCHEMBL1298652 | 0.74 | LRRK2 (0.51) | LRRK2SYKJAK2 | |
| SCHEMBL1298739 | 0.73 | LRRK2 (0.61) | LRRK2SYKJAK2 | |
| SCHEMBL1298712 | 0.72 | LRRK2 (0.57) | LRRK2SYKJAK2 | |
| SCHEMBL1298717 | 0.72 | LRRK2 (0.72) | LRRK2SYKJAK2 | |
| SCHEMBL12655398 | 0.72 | SRC (0.44) | LRRK2MEN1KMT2AJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404677-B2 | Kinase inhibitors | GENOSCO (US) | 2013-03-26 | — | — | US | claimed |
| US-20110269739-A1 | KINASE INHIBITORS | OSCOTEC, INC. (KR) | 2011-11-03 | — | — | US | claimed |
| US-8404677-B2 | Kinase inhibitors | GENOSCO (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404677-B2 | Kinase inhibitors | GENOSCO (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404677-B2 | Kinase inhibitors | GENOSCO (US) | 2013-03-26 | — | — | US | disclosed |
| US-20110269739-A1 | KINASE INHIBITORS | OSCOTEC, INC. (KR) | 2011-11-03 | — | — | US | disclosed |
| US-20110269739-A1 | KINASE INHIBITORS | OSCOTEC, INC. (KR) | 2011-11-03 | — | — | US | disclosed |
| US-20110269739-A1 | KINASE INHIBITORS | OSCOTEC, INC. (KR) | 2011-11-03 | — | — | US | disclosed |
| WO-2011053861-A1 | KINASE INHIBITORS | GENOSCO (US) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269739-A1 | KINASE INHIBITORS | JAK1, LCK, MAP3K20 | LRRK2 436/4885BRAF 52/4885SYK 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.